TNFRSF17 and plasma cell myeloma: In this analysis of an ongoing phase 1, first-in-human clinical study, LCAR-B38M, a CAR T cell therapy directed against 2 distinct BCMA epitopes, displayed a manageable safety profile and demonstrated durable responses in patients with relapsed or refractory multiple myeloma.